Onco Wiki / Indication

HCV-associated Marginal Zone Lymphoma · Sofosbuvir/Velpatasvir 12 weeks

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Trackstandard
Linked regimenREG-DAA-SOF-VEL
IDIND-CHRONIC-HCV-PREVENTION-DAA
TypeIndication
Statusreviewed 2026-05-18 | pending_clinical_signoff
DiseasesDIS-HCV-MZL
SourcesSRC-EASL-HCV-2023 SRC-NCCN-BCELL-2025

Notes

STUB — v0.2-A anchor for the prevention persona (CHARTER §3 scope amendment 2026-05-18, KSS §20 ratification). Requires two-Clinical- Co-Lead signoff per §6.1 dev-mode exemption. Sources cited (EASL HCV 2023, NCCN B-cell 2025). HBV-prophylaxis and decompensated-cirrhosis guards explicit in `do_not_do`. Engine consumption deferred to v0.2 implementation wave: the intent-aware filter in `plan.generate_plan()` + the PreventionPlan shape are not yet implemented. This Indication lands as schema-valid declarative content waiting for that wave (KSS §20.4 step 4). Follow-up authoring TODOs (out of scope for this anchor): - IARC Monograph 100B citation (HCV Group 1) — add as new SRC entity. - AASLD-IDSA HCV guidance citation — add as new SRC entity. - Equivalent prevention-persona Indications for HepB, H. pylori, HPV, EBV, HIV, HTLV-1 (v0.2-A scope continuation).

Used By

Actionability

Algorithms

Indication

Red flag